BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 37185431)

  • 61. Contemporary Axillary Management in cT1-2N0 Breast Cancer with One or Two Positive Sentinel Lymph Nodes: Factors Associated with Completion Axillary Lymph Node Dissection Within the National Cancer Database.
    Stafford AP; Hoskin TL; Day CN; Sanders SB; Boughey JC
    Ann Surg Oncol; 2022 Aug; 29(8):4740-4749. PubMed ID: 35451727
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [A new perspective on axillary dissection in situations of metastatic sentinel node].
    Zedníková I; Ňaršanská A; Hes O; Metelková A; Fiala O; Svoboda T
    Rozhl Chir; 2017; 96(8):346-352. PubMed ID: 29058925
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Role of surgery in patients with synchronous metastatic breast cancer: Is there a need for axillary lymph node removal?
    De Wit A; Arbion F; Desille-Gbaguidi H; Avigdor S; Body G; Ouldamer L
    J Gynecol Obstet Hum Reprod; 2021 Apr; 50(4):101771. PubMed ID: 32335350
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Long-term outcome of pT1a-b, cN0 breast cancer without axillary dissection or staging: a prospective observational study of 1543 women.
    Ingvar C; Ahlgren J; Emdin S; Lofgren L; Nordander M; Niméus E; Arnesson LG
    Br J Surg; 2020 Sep; 107(10):1299-1306. PubMed ID: 32335901
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial.
    Krag DN; Anderson SJ; Julian TB; Brown AM; Harlow SP; Costantino JP; Ashikaga T; Weaver DL; Mamounas EP; Jalovec LM; Frazier TG; Noyes RD; Robidoux A; Scarth HM; Wolmark N
    Lancet Oncol; 2010 Oct; 11(10):927-33. PubMed ID: 20863759
    [TBL] [Abstract][Full Text] [Related]  

  • 66. De-Implementation of Low-Value Care for Women 70 Years of Age or Older with Low-Risk Breast Cancer During the COVID-19 Pandemic.
    Wang T; Weed C; Tseng J; Chung A; Boyle MK; Amersi F; Jutla J; Mirhadi A; Giuliano AE
    Ann Surg Oncol; 2023 Dec; 30(13):8308-8319. PubMed ID: 37624516
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Outcomes of Sentinel Lymph Node-Positive Breast Cancer Patients Treated with Mastectomy Without Axillary Therapy.
    FitzSullivan E; Bassett RL; Kuerer HM; Mittendorf EA; Yi M; Hunt KK; Babiera GV; Caudle AS; Black DM; Bedrosian I; Reyna C; Teshome M; Meric-Bernstam F; Hwang R
    Ann Surg Oncol; 2017 Mar; 24(3):652-659. PubMed ID: 27822630
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Factors Predictive of Sentinel Lymph Node Involvement in Primary Breast Cancer.
    Malter W; Hellmich M; Badian M; Kirn V; Mallmann P; Krämer S
    Anticancer Res; 2018 Jun; 38(6):3657-3662. PubMed ID: 29848724
    [TBL] [Abstract][Full Text] [Related]  

  • 69. De-escalation of axillary surgery in patients outside Z0011 criteria.
    Giannakou A; Gooch J; Gergelis KR; Weiss A
    Surgery; 2023 Aug; 174(2):416-418. PubMed ID: 37156648
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Can We Successfully De-Escalate Axillary Surgery in Women Aged ≥ 70 Years with Ductal Carcinoma in Situ or Early-Stage Breast Cancer Undergoing Mastectomy?
    Matar R; Barrio AV; Sevilimedu V; Le T; Heerdt A; Morrow M; Tadros A
    Ann Surg Oncol; 2022 Apr; 29(4):2263-2272. PubMed ID: 34994896
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Risk factors for regional nodal failure after breast-conserving therapy: regional nodal irradiation reduces rate of axillary failure in patients with four or more positive lymph nodes.
    Grills IS; Kestin LL; Goldstein N; Mitchell C; Martinez A; Ingold J; Vicini FA
    Int J Radiat Oncol Biol Phys; 2003 Jul; 56(3):658-70. PubMed ID: 12788171
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Is repeat sentinel lymph node biopsy possible for surgical axillary staging among patients with ipsilateral breast tumor recurrence?
    Lu X; He M; Yu L; Gou Z
    Cancer; 2023 May; 129(10):1492-1501. PubMed ID: 36807239
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Long-term prognoses and outcomes of axillary lymph node recurrence in 2,578 sentinel lymph node-negative patients for whom axillary lymph node dissection was omitted: results from one Japanese hospital.
    Ogiya A; Kimura K; Nakashima E; Sakai T; Miyagi Y; Iijima K; Morizono H; Makita M; Horii R; Akiyama F; Iwase T
    Breast Cancer; 2016 Mar; 23(2):318-22. PubMed ID: 25376341
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Utilization of Axillary Surgery for Patients With Ductal Carcinoma In Situ: A Report From the National Cancer Data Base.
    Miller ME; Kyrillos A; Yao K; Kantor O; Tseng J; Winchester DJ; Shulman LN
    Ann Surg Oncol; 2016 Oct; 23(10):3337-46. PubMed ID: 27334212
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Selective omission of sentinel lymph node biopsy in mastectomy for ductal carcinoma in situ: identifying eligible candidates.
    Bae SJ; Kook Y; Jang JS; Baek SH; Moon S; Kim JH; Lee SE; Kim MJ; Ahn SG; Jeong J
    Breast Cancer Res; 2024 Apr; 26(1):65. PubMed ID: 38609935
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Does ultrasound evaluation of the axilla increase the rate of axillary lymph node dissection in early stage clinically node negative breast cancer patients?
    Vasigh M; Meshkati Yazd SM; Karoobi M; Hajebi R; Yazdankhah Kenari A
    BMC Surg; 2022 Mar; 22(1):80. PubMed ID: 35241059
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Protocol for the postoperative radiotherapy in N1 breast cancer patients (PORT-N1) trial, a prospective multicenter, randomized, controlled, non-inferiority trial of patients receiving breast-conserving surgery or mastectomy.
    Lee TH; Chang JH; Jang BS; Kim JS; Kim TH; Park W; Kim YB; Kim SS; Han W; Lee HB; Shin KH
    BMC Cancer; 2022 Nov; 22(1):1179. PubMed ID: 36384573
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Evolution of the Use of Completion Axillary Lymph Node Dissection in Patients with T1/2N0M0 Breast Cancer and Tumour-Involved Sentinel Lymph Nodes Undergoing Mastectomy: A Cohort Study.
    Hennigs A; Riedel F; Feißt M; Köpke M; Rezai M; Nitz U; Moderow M; Golatta M; Sohn C; Heil J
    Ann Surg Oncol; 2019 Aug; 26(8):2435-2443. PubMed ID: 31049766
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Cost/accuracy ratio analysis in breast cancer patients undergoing ultrasound-guided fine-needle aspiration cytology, sentinel node biopsy, and frozen section of node.
    Genta F; Zanon E; Camanni M; Deltetto F; Drogo M; Gallo R; Gilardi C
    World J Surg; 2007 Jun; 31(6):1155-63. PubMed ID: 17464539
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Axillary treatment in conservative management of operable breast cancer: dissection or radiotherapy? Results of a randomized study with 15 years of follow-up.
    Louis-Sylvestre C; Clough K; Asselain B; Vilcoq JR; Salmon RJ; Campana F; Fourquet A
    J Clin Oncol; 2004 Jan; 22(1):97-101. PubMed ID: 14701770
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.